It is estimated that osteoporosis affects more than 25 million people in the United States and is the major underlying cause of bone fractures in postmenopausal women and the elderly, while hypertension affects more than half of all Americans over the age of 65. This patent adds to our extensive intellectual property portfolio, and allows us to begin building the clinical substantiation for calcium taurate as we have already done for chromium picolinate. The mineral ingredient category is one which continues to be undervalued, but if properly developed is likely to demonstrate significant health benefits across a wide range of applications that can deliver major health care savings for at-risk populations. We are fortunate to have a position in several proprietary mineral ingredients that have been demonstrated to have clinical benefits in glucose regulation, cardiovascular health and weight management, said Gail Montgomery, President and CEO of Nutrition 21. Forward-looking statements are based on the company's current expectations and are subject to market, competitive and regulatory factors and the other risks and uncertainties indicated from time to time in the company's filings with the Securities and Exchange Commission.
Actual results can differ materially.
The company makes no commitment to disclose any revisions to forward-looking statements.